8-K: Akero Stockholders Approve Novo Nordisk Merger

Akero Therapeutics stockholders have approved the company's acquisition by Novo Nordisk A/S, with early termination of the HSR waiting period also granted.

Summary

• Akero Therapeutics, Inc. stockholders approved the pending acquisition by Novo Nordisk A/S at a special meeting held virtually on December 2, 2025.
• The Merger Proposal was approved with 66,887,600 votes for, 91,361 against, and 50,147 abstentions, representing approximately 81.42% of all outstanding shares eligible to be voted.
• An advisory, non-binding proposal for executive compensation that may be paid in connection with the merger was also approved with 65,621,066 votes for, 1,316,708 against, and 91,334 abstentions.
• The U.S. Federal Trade Commission (FTC) granted early termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act on December 2, 2025, satisfying one of the conditions to the closing of the Merger.
• The merger is expected to close by around year-end, subject to the satisfaction or waiver of other customary closing conditions, including additional antitrust and foreign direct investment clearances.

Sentiment

Score: 8

Explanation: The overwhelming stockholder approval and the early termination of the HSR waiting period significantly de-risk the merger process, indicating a high likelihood of successful completion as expected by year-end.

Positives

• Stockholders overwhelmingly approved the merger with Novo Nordisk A/S.
• The FTC granted early termination of the HSR Act waiting period, removing a significant regulatory hurdle for the merger.
• The advisory vote on executive compensation related to the merger was also approved.
• The company expects the merger to close by around year-end, indicating a clear path forward.

Risks

• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Merger Agreement, including circumstances requiring a party to pay the other party a termination fee.
• The ability for the parties to consummate the Transactions on a timely basis or at all.
• Risks related to non-achievement of the contingent value right (CVR) milestones and that holders of the CVRs will not receive any payments.
• The possibility that competing offers for the Company will be made.
• The possibility that various closing conditions, including the ability to secure regulatory approvals on terms expected at all or in a timely manner, may not be satisfied or waived, or that a governmental entity may prohibit, delay, or refuse to grant approval.
• The effects of the Transactions (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners, or governmental entities.
• The difficulty of predicting the timing or outcome of FDA approvals or actions, if any, particularly for efruxifermin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
• The impact of competitive products and pricing.
• That Parent (Novo Nordisk) may not realize the potential benefits of the Transactions.
• Other business effects, including the effects of industry, economic, or political conditions outside of the parties' control.
• Transaction costs.
• The risk that the Transactions will divert management's attention from the Company's ongoing business operations or otherwise disrupt them.
• Changes in the Company's business during the period between now and the closing of the Transactions.
• Certain restrictions during the pendency of the Transactions that may impact the Company's ability to pursue certain business opportunities or strategic transactions.
• Risks associated with litigation relating to the Transactions.
• The ability to maintain or expand regulatory approvals or commercialize the Company's products.
• That the results of any ongoing or future clinical trials may not satisfy U.S. or non-U.S. regulatory authorities.
• The uncertainty associated with current worldwide economic and financial conditions, including as a result of pandemics and epidemics, rising inflation, increased interest rates, natural disasters, military conflicts, terrorist attacks, and other similar matters.
• Actual or contingent liabilities.

Future Outlook

The parties expect the merger to close by around year-end, subject to the satisfaction or waiver of remaining customary closing conditions, including additional antitrust and foreign direct investment clearances in certain jurisdictions.

Industry Context

This acquisition by Novo Nordisk A/S of Akero Therapeutics reflects a continuing trend of consolidation within the biotechnology and pharmaceutical sectors, particularly for companies with promising assets in high-demand therapeutic areas like metabolic dysfunction-associated steatohepatitis (MASH). Larger pharmaceutical companies often acquire smaller biotechs to bolster their pipelines and gain access to innovative therapies, leveraging their extensive resources for late-stage development and commercialization.

Stakeholder Impact

• Shareholders will receive consideration for their shares as per the merger agreement, including potential contingent value right (CVR) payments.
• Employees face risks related to the ability to retain or hire key personnel, and the merger could impact employment.
• Customers, manufacturers, suppliers, and other business partners may experience effects on their relationships due to the change in ownership.

Next Steps

• Satisfaction or waiver of other customary closing conditions for the merger.
• Receipt of any clearances or approvals under antitrust laws and foreign direct investment laws in certain jurisdictions.
• Expiration or termination of any mandatory waiting periods related to these approvals.
• Consummation of the Merger, expected by around year-end.

Key Dates

Keywords

Akero Therapeutics, Novo Nordisk, Merger, Acquisition, AKRO, HSR Act, FTC, Stockholder Vote, Contingent Value Rights, Biotechnology, Pharmaceuticals, MASH, efruxifermin